Navigation Links
Anti in Biological Technology

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

... which is difficult to treat because some anti anginal medications such as beta blockers ... controlled or intolerant to first-line anti anginal therapies. CV Therapeutics has granted ... controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other ...

Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc

... half alone, and to US$70 Billion in the next 3 years. The worldwide global anti aging market is expected to reach US$115.5 Billion by 2010, and is now one ... industry sectors worldwide. We have a range of products targeted at the anti aging market, including our revolutionary flagship product Vitalife, which ...

Sanofi-aventis Announces Second Quarter 2009 Results

... 1. Results from the SEPIA-ACS1 TIMI 42 phase II trial, evaluating the efficacy and tolerance of otamixaban (an intravenous selective anti Xa factor) in patients with acute coronary syndrome (without ST segment elevation) will also be presented at a plenary session on August 30. ...

SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business

... increasing responsibility over a 9-year period, serving as General Manager for their Paris, France office and Global Finance Director for the CNS and anti Infective business units. Mr. Spector played a key role in integrating newly acquired businesses, growing operations, implementing business ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... pm) -- Involvement of the CSF-1/CSF-1R interaction in the control of angiogenesis Overview: Two different neutralizing rat anti murine CSF-1R monoclonal antibodies (mAb), M279 and AFS98 were evaluated for their effect on mouse corneal angiogenesis and corneal ...

CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Additional Information ...

CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Additional Information ...

CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

... also presented a poster at ASH entitled, "BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active anti T- and B-Cell Agent." Findings presented in this poster support the evaluation of BCX-4208 in the treatment of not only T-cell mediated diseases, ...

CV Therapeutics Statement on Unsolicited Proposal From Astellas

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

... at ASH is as follows: BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase ( PNP ) Inhibitor is a Novel, Potent Orally Active anti T- and B-Cell Agent (Poster # 1547) Saturday, December 6, 2008, 5:30 p.m. - 7:30 p.m. Pacific Time; Hall A A Phase II Study of the ...

CV Therapeutics Reports 2008 Third Quarter Financial Results

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

... remained relatively constant during extended therapy with pegloticase. - Neutralizing antibodies and clinically relevant titers of anti pegloticase IgE were not present in any of the patients with continued use of pegloticase out to as long as 18 months. These ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... Carlesso, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 1843 -- In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody for the treatment of patients with rheumatoid arthritis - Matthew Sleeman, Ph.D., Tuesday, October 28 from 9:00 ...

BioElectronics Corp Aggressively Expands Sales into Middle East

... demand for drug-free medical products," said Andrew J. Whelan, CEO of BioElectronics Corporation. "There is well established need for drug free anti inflammatory therapy in the Middle East which we expect to capture and expand." Whelan explained that Dr. Halawy has had significant sales ...

NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING

... the use of nimotuzumab from the pediatric population to adults with high grade brain tumors. "Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck ...

ULURU Inc. to Present at the 8th World Biomaterials Congress

... be marketed throughout Europe and other international markets. The initial wound dressing containing an active agent, silver, an anti microbial and anti bacterial agent, has recently completed the necessary GLP toxicology studies and we expect to file for 510k approval with the FDA in the second half ...

Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society

... Controversies in Clinical Asthma (Poster Session: Safety Profile, Pharmacokinetics and Biologic Activity of a Single IV Dose of the anti IL-5 Receptor Alpha Antibody MEDI-563 in Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from 8:15 a.m.- 11:00 a.m., Metro ...

Sidec Announces the First Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS

... "During PEGS it became obvious that studying molecular mechanisms is indeed a crucial step in antibody development. Even for some of the best studied anti cancer drug targets, such as CD20, a fundamental understanding of the drug mechanisms is still lacking. Hence, Sidec's Protein Tomography(TM) Award ...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

... Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for Wednesday, April 16, 2008 at 8:00 a.m. -- "Preclinical development of anti B7-H4 therapeutic antibodies" (Abstract #4986, Developmental Immunotherapy Session) - Oral presentation scheduled for Tuesday, April 15, 2008 ...

BioElectronics Announces Canadian Retail Product Launch

... This agreement will usher in a new era for biophysics medicine," said Andrew Whelan, President of BioElectronics. "ActiPatch is a unique drug free, anti inflammatory therapy, which will retail in Canada at market disruptive prices providing therapy for less than $1.50 per day. We are confident and ...

YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION

... is anticipated early in 2008. The poster presentation is entitled "Preliminary Results Of An Escalating Dose (Phase I /II Clinical) Trial Of The anti EGFR Monoclonal Antibody Nimotuzumab In Combination With External Radiotherapy In Patients Diagnosed With Stage IIB, III or IV NSCLC Unsuitable For ...

Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer

... the cells were incubated with APC-labeled anti hCD4-antibody. After washing and ... They were then stained with anti GR antibodies and APC-conjugated ... Reagents anti hCD3 APC antibody, anti hCD4 APC antibody ...

Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer

... with camptothecin or by incubation with anti Fas-antibodies. Different readouts were chosen ... cells were treated for two and four hours with anti Fas antibodies to induce apoptosis. In ... 5 x 105/ml with 1 M camptothecin or 0.5 g/ml anti Fas-antibody for 224 h to induce apoptosis. ...

Turbo Tax Online can teach new Web concepts a business lesson

... design flaws, I can't complain about the ease of use and the ease of mind that this product delivers in straight-forward fashion. TurboTax: The anti 2.0 By no modern definition is TurboTax Online a Web 2.0 product. In fact, some might even scoff that I'd take the time to write about an old ...

Quantitative Analysis of the Cell Cycle in Imaging Applications

... Buffer and stained simultaneously with Alexa Fluor 488 (Invitrogen, A-20000) conjugated anti-BrdU (Cat. No. 555627). Alexa Fluor 647 conjugated anti phospho-Histone H3 (Serine 28) (Cat. No. 558217), and Alexa Fluor 555 (Invitrogen A- 20009) conjugated anti-Ki-67 (Cat. No. 610969) in PBS with 3% ...

The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR

... of CypHer5 Mono NHS Ester.

3. The final dye:protein (D:P) ratio for CypHer5 labelled anti-EGFR was calculated to be 1.4:1 (the CypHer5 anti VSV-G antibody uses a D:P ratio of between 1.5:1 and 3.0:1 for optimum performance).

4. Labelled antibody should immediately be diluted ...

Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes

... type VIII collagen) and immunohistochemical characterization of vascular cells using cell type-specific antibodies (smooth muscle cells: anti smooth muscle actin, Enzo; endothelial cells: von Willebrand factor, Sigma; macrophages: CD68, DAKO) and a peroxidase staining procedure ...
Other Contents
(Date:7/24/2014)... by 45% on average over a 35 year period ... on the impact of humans on declining animal numbers. ... such as insects, spiders, crustaceans, slugs and worms bring ... for crops, decomposition for nutrient cycling, water filtration and ... and led by UCL, Stanford and UCSB, focused ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
(Date:7/25/2014)... Washington, DC (PRWEB) July 25, 2014 ... against some health plans for providing inadequate access to ... serious threats to the health and safety of beneficiaries ... of drug coverage determinations, and CMS is taking quick ... 5, the Atlantic Information Services webinar, “Avoiding Costly ...
(Date:7/25/2014)... iTanSmart is a patented iOS suntan ... provides a tailored approach to eliminating the guesswork from ... skin damage. In his review, Eaton had positive things ... iTanSmart. , Eaton begins his commentary ... organized’ and ‘great alternative’ to its related Android competitor. ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... For rats bearing human breast tumors, exposure to ... the breast cancer drug tamoxifen, according to data published ... American Association for Cancer Research. The negative effects of ... giving rats a melatonin supplement during the night. , ... with hormone receptor-positive breast cancer," said Steven M. Hill, ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
Other TagsOther Tags